BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Digitoxin

A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)

300+ PubMed studies analyzed · 11 RCTs · Evidence Score: 43.3

Research Domains

Digitoxin has been studied across 18 research domains including ❤️ Cardiovascular, 🔬 Oncology, 🫘 Kidney, 🫁 Liver & Detox, 😴 Sleep. The primary research focus is ❤️ Cardiovascular with 24% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Digitoxin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Ouabain
36 shared targets
Digoxin
43 shared targets
Proscillaridin
16 shared targets
Deslanoside
15 shared targets
Digitoxigenin
15 shared targets
cycloheximide
23 shared targets
Emetine
19 shared targets
Melphalan
17 shared targets
Azathioprine
15 shared targets
Digoxigenin
14 shared targets
Loading evidence profile...

This evidence profile for Digitoxin is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.